MedPath

A nutritional intervention study for the evaluation of health benefits of hake consumption in a high cardiovascular risk populatio

Completed
Conditions
Metabolic syndrome
Nutritional, Metabolic, Endocrine
Other metabolic disorders
Registration Number
ISRCTN24439243
Lead Sponsor
Pescanova S.A. (Spain)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
250
Inclusion Criteria

1. Aged between 18 and 75 years, either sex
2. Recruited in outpatients clinics of the participant centres
3. Voluntarily agree with the study protocol and give written informed consent
4. Thorough clinical history and informative meeting has been performed
5. Metabolic syndrome (primary intervention). The presence of metabolic syndrome according to 2004 ATP-III (Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults) criteria will be evaluated. According to the latter, for the diagnosis of the metabolic syndrome, three or more of the following criteria have to be present:
5.1. Central obesity: waist circumference greater than 102 cm in men and greater than 88 cm in women
5.2. Hypertriglyceridemia: triglycerides greater than or equal to 150 mg/dL (greater than or equal to 1.7 mmol/L) or on treatment
5.3. High density lipoprotein (HDL) less than 40 mg/dL (less than 1.1 mmol/L) in men or less than 50 mg/dL (1.3 mmol/L) in women
5.4. Hypertension: systolic blood pressure greater than or equal to 130 mmHg and/or diastolic greater than or equal to 85 mmHg, or on treatment
5.5. Fasting blood glucose greater than or equal to 100 mg/dL (greater than or equal to 5.6 mmol/L) or any other carbohydrate metabolism disorder (including diabetes and glucose intolerance)

Exclusion Criteria

Those who presented any of the following after a thorough clinical history:
1. Previous allergy to fish or Anisakis infection
2. Morbid obesity (body mass index [BMI] greater than 40)
3. Chronic renal failure
4. Creatinine clearance (CrCl) greater than 30
5. Chronic psychopathology
6. Malignancy
7. Refuse to participate
8. Fibrates treatment

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath